Positive Buy Rating for Atossa Therapeutics Driven by Promising Z-endoxifen Efficacy in Breast Cancer

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Atossa Therapeutics (ATOS – Research Report). The associated price target remains the same with $7.00.

Emily Bodnar’s rating is based on Atossa Therapeutics’ strategic decision to advance Z-endoxifen for late-stage development in metastatic breast cancer (mBC). This decision is supported by promising clinical efficacy observed in previous trials, indicating a potential for faster market entry. Z-endoxifen has demonstrated encouraging results across various breast cancer treatment settings, including prophylactic, neoadjuvant, and maintenance treatments, as well as in metastatic settings. The drug has shown potential superiority in efficacy compared to tamoxifen, particularly in patients with both ESR1 mutant and wild-type profiles, which could differentiate it from other treatments.
Furthermore, the data from Phase 1 and Phase 2 studies suggest that Z-endoxifen could offer a significant benefit in progression-free survival (PFS), especially in CDK4/6 inhibitor naive patients. Although the oral SERD space is competitive, the potential broad efficacy of Z-endoxifen could make it a standout option. The anticipation of further regulatory discussions and trial initiations in the coming years adds to the positive outlook, reinforcing the Buy rating.